Download Docs
Export

CUTOMYA

87299360 | Trademark

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed Jan. 12, 2017
Serial No. 87299360
Examining Attorney NANCY CLARKE
Interlocutory Attorney MIKE WEBSTER
Class Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; 006; 018; 044; 046; 051; 052
CUTOMYA
Status Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Opposition 91236429
Omya GmbH, Omya AG v. Allergan Sales, LLC
  • Allergan Sales, LLC;
  • Omya GmbH, Omya AG;
Opposition 87299360
Omya GmbH, et al. v. Allergan Sales, LLC
  • Allergan Sales, LLC;
  • Omya GmbH;
  • Omya AG;
Last Updated: 2 months, 2 weeks ago
Filing Date # Docket Text